Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&uac=148436CN&src=mkmcmr_reeng_recap_mscpedu_activity Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Below are some key learning points to help reinforce the impact of this activity. ☑ The Patient Journey • Understand the patient's treatment journey, including common challenges and adverse events (AEs) • Encourage proactive communication, so patients feel comfortable reporting concerns and AEs to their care team ☑ Managing Adverse Events • Review common AEs of abemaciclib and ribociclib • Educate the patient about what to expect when initiating adjuvant CDK4/6 therapy • Employ strategies to mitigate AEs, including the potential of a lower starting dose of abemaciclib and dose reduction ☑ Monitoring for Recurrence • Review the monitoring guidelines for CDK4/6 inhibitors • Assess your care models for monitoring patients on adjuvant CDK4/6 therapy ☑ Develop best practices for managing the growing number of patients on adjuvant CDK4/6 therapy • Train oncology coaches • Work with your intraprofessional and interprofessional team • Use patient self-reporting tools